TY - JOUR
T1 - CDK9 inhibitors in acute myeloid leukemia
AU - Boffo, Silvia
AU - Damato, Angela
AU - Alfano, Luigi
AU - Giordano, Antonio
PY - 2018/2/23
Y1 - 2018/2/23
N2 - Current treatment for acute myeloid leukemia (AML) is less than optimal, but increased understanding of disease pathobiology and genomics has led to clinical investigation of novel targeted therapies and rational combinations. Targeting the cyclin-dependent kinase 9 (CDK9) pathway, which is dysregulated in AML, is an attractive approach. Inhibition of CDK9 leads to downregulation of cell survival genes regulated by super enhancers such as MCL-1, MYC, and cyclin D1. As CDK9 inhibitors are nonselective, predictive biomarkers that may help identify patients most likely to respond to CDK9 inhibitors are now being utilized, with the goal of improving efficacy and safety.
AB - Current treatment for acute myeloid leukemia (AML) is less than optimal, but increased understanding of disease pathobiology and genomics has led to clinical investigation of novel targeted therapies and rational combinations. Targeting the cyclin-dependent kinase 9 (CDK9) pathway, which is dysregulated in AML, is an attractive approach. Inhibition of CDK9 leads to downregulation of cell survival genes regulated by super enhancers such as MCL-1, MYC, and cyclin D1. As CDK9 inhibitors are nonselective, predictive biomarkers that may help identify patients most likely to respond to CDK9 inhibitors are now being utilized, with the goal of improving efficacy and safety.
KW - Acute myeloid leukemia
KW - CDK9 inhibitor
KW - MCL-1
KW - MYC
KW - P-TEFb
KW - Positive transcription elongation factor b
UR - http://www.scopus.com/inward/record.url?scp=85042503905&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042503905&partnerID=8YFLogxK
U2 - 10.1186/s13046-018-0704-8
DO - 10.1186/s13046-018-0704-8
M3 - Review article
AN - SCOPUS:85042503905
VL - 37
JO - Journal of Experimental and Clinical Cancer Research
JF - Journal of Experimental and Clinical Cancer Research
SN - 0392-9078
IS - 1
M1 - 36
ER -